Dr. August Wolff Arzneimittel GmbH & Co. KG and Mercachem B.V. start two drug development collaborations
Dr. August Wolff GmbH & Co. KG Arzneimittel and Mercachem have started two multi-year drug development collaborations. Dr. August Wolff GmbH & Co. KG Arzneimittel have licensed a number of patents from universities that cover novel classes of molecules with potential use in dermatology. Mercachem is responsible for medicinal chemistry and project management with the goal to further improve the properties of these molecules and to develop them into clinical candidates.
‘We are of course very pleased that Dr. August Wolff GmbH & Co. KG Arzneimittel has selected Mercachem as its partner to help the company with the new strategy to focus more on the development of novel innovative products’ says Frank Leemhuis, Managing Director of Mercachem, ‘We believe that our reputation for delivering high quality work and creating novel molecules besides our excellent synthetic skills have contributed to the positive decision of Dr. August Wolff GmbH & Co. KG Arzneimittel to work with us.’
Professor Christoph Abels, Medical Director, comments: ‘Dr. August Wolff GmbH & Co. KG Arzneimittel wants to introduce novel and safe products in the areas of dermatology and gynecology as fast as possible into the market. Working in the field of drug development without a large in-house research team geared for this purpose, our strategy is to rely on high-quality service providers that offer ‘fit-for-purpose’ solutions and complement our knowledge. Since Dr. August Wolff GmbH & Co. KG Arzneimittel is looking for alternative approaches to solve unmet medical needs, we believe that the people at Mercachem meet our needs as an innovative family business most adequately.’
Topics
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

LipiDiDiet finds long-lasting and broad effects of nutritional intervention in early Alzheimer’s - 20 percent less brain shrinkage in patients who received a nutrient cocktail than in those in the control group

Bioplastics from Waste Fats - Using bacteria to replace plastics derived from fossil oil

University spinout receives £1.2 million to tackle antimicrobial resistance

Cooling speeds up electrons in bacterial nanowires - This is very surprising because cooling typically freezes electrons and slows them down in organic materials
Gene Bridges granted Korean Patent for Recombineering Technology

Autoimmune Reaction Successfully Halted in Early Stage Islet Autoimmunity
Cangene's VIG (Vaccinia Immune Globulin Intravenous) contract with U.S. government extended for another five years

Illuminating the genome - RNA-guided endonuclease - in situ labelling, a new CRISPR/Cas9 based molecular visualisation method

A.R.C.O.- Chemie GmbH - Herdecke, Germany
St. Anna Kinderkrebsforschung - Wien, Austria
